| abstract |
The present invention relates to compositions and methods for producing modified hematopoietic stem or progenitor cells. One aspect of the invention comprises a modified hematopoietic stem or progenitor cell comprising a nucleic acid capable of reducing the expression of an endogenous gene or part thereof, wherein said endogenous gene is a chimeric antigen receptor (CAR) Encoding a polypeptide comprising an antigenic domain targeted to Another aspect of the invention includes methods for producing modified hematopoietic stem or progenitor cells. Also included are methods and pharmaceutical compositions comprising modified cells for adoptive therapy and for treating conditions such as autoimmune diseases or cancer. |